Synergistic interactions among antifolates

Pharmacology and Therapeutics

Volumn 85, Issue 3, 2000, Pages 183-190

  Kisliuk, Roy L ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Antifolates; Dihydrofolate reductase; Glycinamide ribonucleotide formyltransferase; Synergy; Thymidylate synthase

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; METHOTREXATE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; TETRAHYDROFOLIC ACID DERIVATIVE; THYMIDINE PHOSPHATE; TRIMETREXATE;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; FOLATE METABOLISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; CELL CULTURE TECHNIQUES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; LYMPHOMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PTEROYLPOLYGLUTAMIC ACIDS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0034026479     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00056-X     Document Type: Conference Paper

References (20)

1. Ahmad S.I., Kirk S.H., Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol. 52:1998;591-625.
2. Bloom L.A. Using computer modeling to explain the "Kisliuk effect." Proc Am Assoc Cancer Res. 39:1998;431.
3. Boritzki T.J., Zhang C., Bartlett C.A., Jackson R.C. AG2034. a Garft inhibitor with selective cytotoxicity to cells that lack a gi checkpoint Jackman A. Antifolate Drugs in Cancer Therapy. 1999;281-292 Humana Press, Totowa.
4. Bunni M., Doig M., Donato H., Kesavan V., Priest D.G. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res. 48:1988;3398-3404.
5. Faessel H.M., Slocum H.K., Jackson R.C., Boritzki T.J., Rustum Y.M., Nair M.G., Greco W.R. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes. the critical role of polyglutamylation Cancer Res. 58:1998;3036-3050.
6. Faessel H.M., Slocum H.K., Rustum Y.M., Greco W.R. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl-(S) -ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034). Biochem Pharmacol. 57:1999;567-577.
7. Ferguson K., Boschelli D., Hoffman P., Oronsky A., Whitely J., Webber S., Galivan J., Freisheim J., Hynes J., Kerwar S.S. Synergy between 5,10-dideaza-5,6,7,8-tetrahydrofolic acid and methotrexate in mice bearing L1210 tumors. Cancer Chemother Pharmacol. 25:1990;173-176.
8. Galivan J., Nimec Z., Rhee M. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N-10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine. Cancer Res. 47:1988;5256-5260. a.
9. Galivan J., Nimec Z., Rhee M., Boschelli D., Oronsky A.L., Kerwar S.S. Antifolate drug interactions. enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate Cancer Res. 48:1988;2421-2425. b.
10. Galivan J., Rhee M.S., Johnson T.B., Dilwith R., Nair M.G., Bunni M., Priest D.G. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihdyrofolate reductase. J Biol Chem. 264:1989;10685-10692.
11. Gaumont Y., Kisliuk R.L., Emkey R., Piper J.R., Nair M.G. Folate enhancement of antifolate synergism. Curtius H.C., Ghisla S., Blau N. Chemistry and Biology of Pteridines. 1989;1131-1136 Walter de Gruyter, Berlin.
12. Gaumont Y., Kisliuk R.L., Parsons J.C., Greco W.R. Quantitation of folic acid enhancement of antifolate synergism. Cancer Res. 52:1992;2228-2235.
13. Greco W.R., Bravo G., Parsons J.C. The search for synergy. a critical review from a response surface perspective Pharm Rev. 47:1995;331-385.
14. Harvey R.J. Synergism in the folate pathway. Rev Infect Dis. 4:1982;255-260.
15. Jackson R.C. Antifolate drugs. Past and future perspectives. Jackman A. Antifolate Drugs in Cancer Therapy. 1999;1-12 Humana Press, Totowa.
16. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Schornagel J.H., Pinedo H.M., Peters G.J., Assaraf Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of folate resistance. J Biol Chem. 273:1998;30189-30198.
17. Kisliuk R.L. Folate biochemistry in relation to antifolate selectivity. Jackman A. Antifolate Drugs in Cancer Therapy. 1999;13-36 Humana Press, Totowa.
18. Kisliuk R.L., Gaumont Y., Kumar P., Coutts M., Nair M.G., Nanavati N.T., Kalman T.I. The effect of polyglutamylation on the inhibitory activity of folate analogs. Goldman I.D. Proceedings of the Second Workshop on Folyl and Antifolyl Polyglutamates. 1985;319-328 Praeger, New York.
19. Kisliuk R.L., Gaumont Y., Powers J.F., Thorndike J., Nair M.G., Piper J.R. Synergistic growth inhibition by combination of antifolates. Picciano M.F., Stokstad E.L.R., Gregory J.F. III Folic Acid Metabolism in Health and Disease. 1990;79-89 Wiley-Liss, New York.
20. Tse A., Moran R.G. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate. J Biol Chem. 273:1998;25944-25952.